MerLion Pharmaceuticals Completes Growth Financing Round
05/18/2021 | 03:30am EDT
Send by mail :
Message :
TM
Berlin, (18/05/2021) - MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors.
The funds raised will primarily be used to finance the production and market launch of MerLion’s US FDA and Health Canada approved drug Xtoro
TM, an otic suspension containing finafloxacin for treatment of ear infections.
In addition to existing investors such as HeidelbergCapital and Vl Partners, new strategic investors such as Denk Pharma GmbH & Co. KG have taken part in the round. Further details were not disclosed.
Press Release : MerLion Pharmaceuticals Completes Growth Financing Round
05/18/2021 | 03:31am EDT
Send by mail :
Message :
Required fields - Proceeds will be used to facilitate MerLion`s production and market
launch of Xtoro(TM) Berlin, (18/05/2021) - MerLion Pharmaceuticals GmbH (MerLion), a
biopharmaceutical company focused on research and development of novel
antibiotics for the treatment of serious bacterial infections, today
announced the successful completion of a growth financing round raised
via a private placement to European strategic investors. The funds raised will primarily be used to finance the production and
market launch of MerLion s US FDA and Health Canada approved drug
Xtoro(TM) , an otic suspension containing finafloxacin for treatment of